文献速递临床试验与 GCP基础与转化研究

黄芪与丹参注射液对稳定性冠心病患者血清炎症标志物影响的随机对照试验方案

Effects of Astragalus injection and Salvia Miltiorrhiza injection on serum inflammatory markers in patients with stable coronary heart disease: a randomized controlled trial protocol.
PubMed 文献 · Trials · 2020-03-17

本研究为随机、盲法、前瞻性、单中心试验方案,计划纳入160例稳定性冠心病患者,随机分为三个治疗组和安慰剂对照组,干预7天并随访28天,主要评价血清炎症标志物等指标,旨在为中药提取物治疗冠心病提供临床证据。

要点

  • 黄芪与丹参注射液可能通过抗炎途径改善稳定性冠心病。
  • 主要结局包括hs-CRP、MCP-1、IL-6等多种炎症标志物。
  • 试验已在中国临床试验注册中心注册(ChiCTR1900021590)。

核心结论

  • 该随机对照试验方案旨在评估黄芪与丹参注射液对稳定性冠心病患者血清炎症标志物的影响,结果预期为冠心病治疗提供临床证据。

研究设计与样本

  • 采用随机、盲法、前瞻性、单中心试验设计,计划纳入160例合格患者,等量随机分配至三个治疗组和安慰剂对照组。

主要发现

  • 原文未报告研究结果,仅描述将评估细胞计数、hs-CRP、MCP-1、IL-6、IL-1β、IL-8、IL-18、IL-10、TNF-α、OX-LDL、心绞痛分级和中医症状变化量表等主要指标。

关键数值与推荐

  • 患者入组后每24小时接受适当治疗,持续7天,随访28天。
  • 主要评价指标包括细胞计数、血清hs-CRP、MCP-1、IL-6、IL-1β、IL-8、IL-18、IL-10、TNF-α、OX-LDL、心绞痛分级和中医症状变化量表。
  • 次要指标包括BNP、cTn、CK-MB、H-FABP、肝肾功能及凝血功能,并密切监测不良事件。

临床怎么用

  • 若试验结果支持,黄芪与丹参注射液可能成为稳定性冠心病抗炎治疗的补充选项,但需等待结果发表。

局限性

  • 原文未报告研究局限性;方案为单中心设计,样本量160例,结果尚未可得。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronary heart disease (CHD) is a clinical syndrome caused by coronary atherosclerosis (AS) or functional changes in coronary arteries. We have previously reported that astragaloside IV (in astragalus) and tanshinone IIA (in Salvia miltiorrhiza) improve myocardial ischemic injury. METHODS: This study will employ the randomized, blinded, prospective, single-center experiments approach. Briefly, a total of 160 eligible patients will be equally randomized into three treatment groups and placebo control groups. Patients will receive appropriate treatments every 24 h for seven days after enrollment and followed up for 28 days. The main evaluation indicators will be cell count, serum high-sensitivity C-reactive protein (hs-CRP) level, monocyte chemoattractant protein 1 (MCP-1), interleukin-6 (IL-6), interleukin-1β (IL-1β), interleukin-8 (IL-8), interleukin-18 (IL-18), interleukin-10 (IL-10), tumor necrosis factor (TNF)-α, oxidized low density lipoprotein (OX-LDL), angina grade, and Traditional Chinese Medicine (TCM) symptom changes scale. Secondary indicators to be evaluated will include B-type natriuretic peptide (BNP) levels, troponin (cTn), muscle enzyme isoenzyme (CK-MB), heart-type fatty acid binding protein (H-FABP), liver and renal functions, as well as blood coagulation. Close monitoring of adverse events during the trial will also be conducted. DISCUSSION: This randomized controlled trial of Chinese herbal extracts for the treatment of coronary heart disease will generate results that are expected to provide valuable clinical evidence to inform future development of therapies towards management of CHD. TRIAL REGISTRATION: China Clinical Trial Registration Center, ChiCTR1900021590. Registered on 28 February 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Luo Z, Liu Y, Zhao Z, et al. Effects of Astragalus injection and Salvia Miltiorrhiza injection on serum inflammatory markers in patients with stable coronary heart disease: a randomized controlled trial protocol. Trials. 2020. PMID: 32178701. doi:10.1186/s13063-020-4109-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。